clinical trial study cath lab ep heart failure treatments cardiofit biocontrol

A multidisciplinary team of experts in heart failure, cardiac arrhythmia and neurosurgery at Mount Sinai Hospital in New York City are testing nerve stimulation in the neck as a therapy for heart failure patients to potentially help relieve their debilitating symptoms of fatigue, shortness of breath and heart arrhythmias while reducing their hospitalizations.

The 2014 Top 10 Health Technology Hazards list raises awareness of the potential dangers associated with the use of medical devices and helps healthcare providers minimize the risk of technology-related adverse events.

Video game technology is being applied to imaging by German researchers, who will be presenting their findings at RSNA 2013. Xbox in the operating room and the use of video game controllers in visualizing organs and tumors, an ultra-sensitive MRI technology for early detection of cancer and a one-stop stroke management technology are among advances coming from scientists affiliated with the German Federal Ministry for Education and Research (BMBF):

Neovasc Inc. reported the results from its COSIRA (coronary sinus reducer for treatment of refractory angina) trial assessing the efficacy and safety of the Neovasc Reducer, a percutaneous device for the treatment of refractory angina.

Esaote will showcase Prevention Suite, a unique package of ultrasound imaging modalities for both cardiac and vascular investigations at the EuroEcho-Imaging 2013 conference Dec. 11-14 in Istanbul, Turkey.

renal stenting
CORAL trial, primary endpoint, renal stenting
CORAL trial, renal stenting
CORAL trial subgroups, renal stenting

The use of renal stenting in combination with medication-based therapy to treat hypertension showed no improvement in patient outcomes over the use of medications alone in treating hypertension. The results from the highly-anticipated CORAL trial were presented at the American Heart Assn. (AHA) 2013 Scientific Sessions in Dallas.
laa occluders structural heart atrial fibrillation atricure atriclip exclusion

AtriCure Inc., a developer of solutions to treat atrial fibrillation, announced the U.S. Food and Drug Administration’s (FDA’s) approval to begin enrollment in a clinical study of AtriCure’s AtriClip Left Atrial Appendage Exclusion System.
Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now